Skip to main content

Table 1 Antimicrobial susceptibility results of 55 CRKP clinical isolates

From: Characterization of fosfomycin resistance and molecular epidemiology among carbapenem-resistant Klebsiella pneumoniae strains from two tertiary hospitals in China

Antimicrobial agents

MIC (μg/mL)

number of isolates (%)

Range

MIC50

MIC90

S

I

R

CTX

256–> 256

> 256

> 256

0 (0.0)

0 (0.0)

55 (100)

CRO

256–> 256

> 256

> 256

0 (0.0)

0 (0.0)

55 (100)

FEP

128 – > 256

> 256

> 256

0 (0.0)

0 (0.0)

55 (100)

MEM

8–> 256

256

> 256

0 (0.0)

0 (0.0)

55 (100)

ATM

2–> 256

> 256

> 256

1 (1.8)

0 (0.0)

54 (98.2)

FOS

256–> 512

> 512

> 512

0 (0.0)

0 (0.0)

55 (100)

AK

1–> 256

> 256

> 256

4 (7.3)

0 (0.0)

51 (92.7)

TGC

1–8

2

8

22 (40.0)

8 (14.5)

25 (45.5)

PB

0.25–1

0.5

0.5

55 (100)

0 (0.0)

0 (0.0)

  1. MIC50, minimum inhibitory concentration for 50% of the isolates; MIC90, minimum inhibitory concentration for 90% of the isolates
  2. S susceptibility, I intermediate, R resistance
  3. CTX cefotaxime, CRO ceftriaxone, FEP cefepime, MEM meropenem, ATM aztreonam, FOS fosfomycin, AK amikacin, TGC tigecycline, PB polymyxin B
  4. The susceptibility profiles were analyzed according to the CLSI guidelines for CTX, CRO, FEP, MEM, ATM, FOS and AK, and EUCAST for PB and TGC